This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Print Page   |   Contact Us   |   Sign In   |   Register
Community Search
WCBP 2017: Roundtable Information
Share |

 

Roundtable Session 1: Tuesday, January 24, 14:45 - 15:45


 

               
 

   Table 1: Process Performance Qualification for Accelerated Products
    Room: Cabinet Room

    Facilitator: Josh Grieco, Genentech, a Member of the Roche Group

    Scribe: Julia O'Neill, Tunnel Consulting

    To view the scope and discussion notes, click here.

 

   Table 2: Combination Products / Therapies:Development of Control Strategies
    Room: Cabinet Room

    Facilitator: Pat Rancatore, Genentech, a Member of the Roche Group

    Scribe: Peter Johnson, 3M Drug Delivery Systems

      To view the scope and discussion notes, click here.

 

   Table 3: Innovating Purity/Impurity Testing during LCM (Analytical - LCM)
    Room: Cabinet Room

    Facilitator: Narasaiah Dontha, Celgene 

    Scribe: Anders Lund, Sanofi

    To view the scope and discussion notes, click here.

 

    Table 4: Surrogate Sterility Testing
     Room: Cabinet Room

     Facilitator: Brian K. Nunnally, Biogen 

     Scribe: Allison Lehtinen, Biogen

     To view the scope and discussion notes, click here.

 

   Table 5: Scope of Analytical Target Profiles (ATP) in Biotherapeutiv Drug Development
    RoomCabinet Room

    Facilitator: Amisha Kizhakkedathu, Pfizer, Inc

   Scribe: Sherry Guo, Genentech, a Member of the Roche Group

    To view the scope and discussion notes, click here.

 

   Table 6: QbD for Analytical Methods
    Room: Cabinet Room

    Facilitator: Ed Moore, University of Illinois 

    Scribe: Ken Miller, MedImmune

    To view the scope and discussion notes, click here.

 

   Table 7: Analysis of Non-protein Particles
    Room: Cabinet Room

    Facilitator: Santosh Yadav, Merck & Co., Inc.

    Scribe: Petra Cavallaro, Eli Lilly and Company

    To view the scope and discussion notes, click here.

 

   Table 8: Applying Biosimilar Development Approaches to Innovative Products
    Room: Cabinet Room

    FacilitatorCarol Krantz, Sierra Oncology

   Scribe : Jason Rouse, Pfizer, Inc. 

   To view the scope and discussion notes, click here.

 

   Table 9: Regulatory Requirements for Gene Editing
    Room: Cabinet Room

    Facilitator: Joann Parker, Pfizer, Inc.

    Scribe: Ilona Reischl, AGES

    To view the scope and discussion notes, click here.

 

   Table 10: Forced Degradation as Part of Comparability
    Room: Cabinet Room

    Facilitator: Tapan Das, Bristol-Myers Squibb Company

    Scribe: Holly Cargill, Pfizer, Inc. 

   To view the scope and discussion notes, click here.

 

   Table 11: Antibodies with Effector Function: Development and Comparability Strategies
    Room: District Ballroom

    Facilitator: Mike Lewis, Janssen R&D, LLC

    Scribe: Reed Harris, Genentech, a Member of the Roche Group

    To view the scope and discussion notes, click here.

 

   Table 12: The Quality Overall Summary: Making the Best of It
    Room: District Ballroom

    Facilitator: Allison Wolf, Eli Lilly and Company 

    Scribe: Melia Grim, MedImmune

    To view the scope and discussion notes, click here.

 

   Table 13: Introducing a New Biologic into Your Commercial Facility: Best Practices
    Room: District Ballroom

    Facilitator: Lou Antinori, Pfizer, Inc.

    Scribe: Gerald DiDonato, Bristol-Myers Squibb Company

    To view the scope and discussion notes, click here.

 

   Table 14: Advances in Gene Therapy Manufacturing and Associated CMC Challenges
    Room: District Ballroom

    Facilitator: Francis Poulin, Genzyme 

    Scribe: Mike Abernathy, Amgen Inc.

    To view the scope and discussion notes, click here.

 

   Table 15: Host Cell Protein: Implementing Risk Assessment Strategies
    Room: District Ballroom

    Facilitator: Bharat Dixit 

    Scribe: Marisa Jones, GlaxoSmithKline 

    To view the scope and discussion notes, click here.

 

   Table 16: In-use Stability: How to Develop a Plan for your Product
    Room: District Ballroom

    Facilitator: Tim Schofield, GlaxoSmithKline 

    Scribe: Justin Sperry, Pfizer, Inc.

    To view the scope and discussion notes, click here.

 

   Table 17: Novel Modalities and their Comparability Challenges during Late Stage Development
    Room: District Ballroom

    Facilitator: James Carroll, Pfizer, Inc. 

    Scribe: Nick Bond, MedImmune 

    To view the scope and discussion notes, click here.

 

   Table 18: Streamlining In-country Testing Requirements, Transfers, and Post-approval Changes for         Global Markets
    Room: District Ballroom

    Facilitator: Mary Beth Pelletier, Biogen 

    Scribe: Justin Aldridge, Biogen

    To view the scope and discussion notes, click here.

 

   Table 19: Method Transfers: Industry and Regulatory Perspectives
    Room: District Ballroom

    Facilitator: Tam Soden, Janssen R&D, LLC

    Scribe: John Kim, Teva Pharmaceutical Industries Ltd.

    To view the scope and discussion notes, click here.

 

   Table 20: Visible Particulates
    Room: District Ballroom

    Facilitator: Tami Wu, Seattle Genetics, Inc.  

    Scribe: Jackie Moxham, Pfizer, Inc.

    To view the scope and discussion notes, click here. 

 

   Table 21: The Mechanisms of Polysorbate Degradation: Implications of this Degradation and Ways of Minimizing It
    Room: Palm Court Ballroom

    Facilitator: Barthelemy Demeule, Genentech, a Member of the Roche Group 

    Scribe: Atanas Koulov, Lonza Biologics

    To view the scope and discussion questions, click here.

 

   Table 22: Viral Segregation Practices
    Room: Palm Court Ballroom

    Facilitator: Michelle Wang, Bristol-Myers Squibb Company

    Scribe: Roman Drews, LFB-USA 

    To view the scope and discussion questions, click here. 

 

   Table 23: Tech Transfer into Manufacturing: The Initial Risk Assessment
    RoomPalm Court Ballroom

    Facilitator: Weiwei Hu, Celgene Corporation

    Scribe: Patsy Lewis, Seattle Genetics, Inc. 

    To view the scope and discussion notes, click here.

 

   Table 24: Quality by Design: Value and Challenges
    Room: Palm Court Ballroom

    Facilitator: Lynn Gennaro, Genentech, a Member of the Roche Group

    Scribe: Michael Chang, Shire

    To view the scope and discussion notes, click here. 

 

   Table 25: Raw/Ancillary Materials: Risk Management and Control
    Room: Palm Court Ballroom

    Facilitator: Maura Kibbey, U.S. Pharmacopeia

    Scribe: Emily Shacter, ThinkFDA

    To view the scope and discussion notes, click here.

 

   Table 26: Preparing for PAI and HA inspections: Trends and General Guidelines
    Room: Palm Court Ballroom

    Facilitator: Nancy Kavanaugh, MedImmune

    Scribe: Cishan (Kevin) Li, CDER, FDA

    To view the scope and discussion notes, click here. 

 

   Table 27: Shipping and Cold Chain Management
    Room: Palm Court Ballroom

    Facilitator: Kathy Lee, Eli Lilly and Company

    Scribe: Kevin King, Pfizer, Inc.

    To view the scope and discussion notes, click here.

 

   Table 28: Linking Process Variability to Clinical Experience
    Room: Palm Court Ballroom

    Facilitator: Jr Dobbins, Eli Lilly and Company

    Scribe: Jackie Macaulay, Pfizer, Inc. 

    To view the scope and discussion questions, click here. 

 

   Table 29: Potency Testing for Vaccine Development
    Room: Palm Court Ballroom

    Facilitator: Arjen Scholten, Janssen Vaccines 

    Scribe: John Amery, Pfizer, Inc.

    To view the scope and discussion notes, click here.

 

   Table 30: Regulatory Expectations and Challenges in China
    Room: Palm Court Ballroom

    Facilitator: Chi-Ting Huang 

    Scribe: MingFang Hong, Merck

    To view the scope and discussion notes, click here. 

 

 


Roundtable Session 2: Wednesday, January 25, 16:30 - 17:30



    
    Table 31: Assays Used in Process Monitoring: Lifecycle Management

    Room: Cabinet Room

    Facilitator: Julia O'Neill, Tunnell Consulting 
    Scribe: Heidi Holovics, Pfizer, Inc. 

      To view notes from this discussion, see Table 35. 

 

   Table 32: Fingerprinting Approaches: Impact for Biosimilars and Innovative Products
    Room:Cabinet Room

    Facilitator: Brian DiPaolo, AbbVie, Inc. 
    Scribe: Valerie Tsang, Biogen

      To view the scope and discussion notes click here.

 

   Table 33: Post-approval Analytical Comparability: Global Convergence
    Room: Cabinet Room

    Facilitator: Rob McCombie, Genentech, a Member of the Roche Group
    Scribe: Mike Jankowski, Pfizer, Inc.

      To view the scope and discussion notes, click here.

 

   Table 34: Novel Modalities: Process and Analytical Challenges
    Room: Cabinet Room

    Facilitator: Jessika Feliciano, Janssen R&D, LLC
    Scribe: Kris Antonsen, BioMarin Pharmaceuticals 

      To view the scope and discussion notes, click here.

 

   Table 35: Method Changes in a Commercial Environment
    Room: Cabinet Room

    Facilitator: Justin Aldridge, Biogen
    Scribe: Mary Beth Pelletier,  
Biogen

     To view the scope and discussion notes, click here.

 

   Table 36: Biosimilars: Ways to Manage Challenges Post-approval
    Room: Cabinet Room

    Facilitator: Patsy Lewis, Seattle Genetics, Inc.
    Scribe: Carmilia Jimenez Ramirez, Gilead Sciences 

      To view the scope and discussion notes, click here.

 

   Table 37: QbD and Design Space: Post-approval Experiences
    Room: Cabinet Room

    Facilitator: Christof Finkler, F. Hoffman - La Roche
    Scribe: Jette Wypych, Amgen Inc.

     To view the scope and discussion questions, click here.

 

   Table 38: Between Shipping and Administration: What is the Product Quality of the
    Drug Patients Actually Receive?
 
    Room: Cabinet Room

    Facilitator: Arun Tholudur, Amgen Inc.
    Scribe: Bryan Silvey, Kite Pharma 

      To view the scope and discussion notes, click here.

 

   Table 39: ID Testing: Managing Satellite Samples 
    Room: Cabinet Room

    Facilitator: Dieter Schmalzing, Genentech, a Member of the Roche Group 
    Scribe: Zahra Shahrokh, STC Biologics

     To view the scope and discussion notes, click here. 

 

   Table 40: WHO: Changes to the Naming Conventions for mAbs
    Room: Cabinet Room

    Facilitator: Patrick Swann, Biogen
    Scribe: Shadia Zaman, CDER, FDA

     To view the scope and discussion notes, click here.

 

   Table 41: Patient Access: Bringing Biologics to Everyone
    Room: District Ballroom

    Facilitator: Scott Whitlock, Seattle Genetics, Inc. 
    Scribe: Stephen Hadley,
 Bill & Melinda Gates Foundation

      To view the scope and discussion notes, click here.

 

   Table 42: Validation of Research Test Kits for QC Lot Release
    Room: District Ballroom

    Facilitator: Ken Miller, MedImmune
    Scribe: Maura Kibbey, U.S. Pharmacopeia

      To view the scope and discussion notes, click here.

 

   Table 43: PAT: Aseptic Sampling from Stainless and Disposable Bioreactors
    Room: District Ballroom

    Facilitator: Doug Richardson, Merck
    Scribe:Jeffrey Weber, Pfizer, Inc. 

     To view the scope and discussion notes, click here.

 

   Table 44: Control Strategies for Surfactants in Biopharmaceuticals
    Room: District Ballroom

    Facilitator: Jamie Moore, Genentech, a Member of the Roche Group
    Scribe: Carsten Jahn, AbbVie, Inc.

     To view the scope and discussion notes, click here.

 

   Table 45: Multi-attribute Methods (MAM)
    Room: District Ballroom

    Facilitator: Richard Rogers, Just Biotherapeutics 
    Scribe: Mike Abernathy, Amgen Inc. 

    To view the scope and discussion notes, click here.

 

   Table 46: Reduced Stability Testing Approaches for Biologics/Biotech Products
    Room: District Ballroom

    Facilitator: Brian K. Nunnally, Biogen
    Scribe: Allison Torgesen, Seattle Genetics, Inc.

     To view the scope and discussion notes, click here.

 

   Table 47: Potency Tests for Vaccines: Hard to Develop or Change?
    Room: District Ballroom

    Facilitator: Sally Seaver, Seaver Associates LLC 
    Scribe: Carol Krantz, ProNAI Therapeutics 

     To view the scope and discussion notes, click here.

 

   Table 48: Process Performance Qualification for Accelerated Products
    Room: District Ballroom

    Facilitator: Trevor Swartz, Genentech, a Member of the Roche Group
    Scribe: Annie Sturgess, Bristol-Myers Squibb Company

     To view the scope and discussion notes, click here.

 

   Table 49: Combination Products / Therapies: Development of Control Strategies
    RoomDistrict Ballroom

    Facilitator: Sherri Biondi, Genentech, a Member of the Roche Group
    Scribe: Peter Johnson, 3M Drug Delivery Systems

     To view the scope and discussion notes, click here.

 

   Table 50: Antibodies with Effector Function: Development and Comparability Strategies
    Room: District Ballroom

    Facilitator: John Kim, Teva Pharmaceutical Industries Ltd.  
    Scribe: William Matousek, Regeneron Pharmaceuticals 

      To view the scope and discussion notes, click here.

 

   Table 51: The Quality Dossier Overall Summary: Making the Best of It
    Room: Palm Court Ballroom

    Facilitator: Michelle Frazier, Coherus Biosciences 
    Scribe: Reed Harris, Genentech, a Member of the Roche Group

     To view the scope and discussion notes, click here.

 

   Table 52: Preparing for PAI and HA Inspections:  Trends and General Guidelines
    Room: Palm Court Ballroom

    Facilitator: Jessica Snow, Bristol-Myers Squibb Company
    Scribe: Kristen Nickens, CDER, FDA

      To view the scope and discussion notes, click here.

 

   Table 53: Linking Process Variability to Clinical Experience
    Room: Palm Court Ballroom

    Facilitator: Juliana Kretsinger, Eli Lilly and Company
    Scribe: Kim Wolfram, Biogen

     To view the scope and discussion notes, click here.

 

   Table 54: Raw Materials: Risk Management and Control
    Room: Palm Court Ballroom

    Facilitator: Sarah Demmon, Eli Lilly and Company 
    Scribe: Charles Morgan, Genentech, a Member of the Roche Group

      To view the scope and discussion notes, click here.

 

   Table 55: Tech Transfer from R&D into Commercial Manufacturing: The Initial Risk
    Assessment

    Room: Palm Court Ballroom

    Facilitator: Sid Advant, Celgene Corporation
    Scribe: Chris Broomell, Takeda Pharmaceuticals North America, Inc.

     To view the scope and discussion questions, click here. 

 

   Table 56: Viral Segregation Practices
    Room: Palm Court Ballroom

    Facilitator: Roman Drews, LFB-USA
    Scribe: Nina Brahme, CDER, FDA

       To view notes from this discussion, see Table 22.

 

   Table 57: In-use Stability: How to Develop a Plan for your Product
    Room: Palm Court Ballroom

    Facilitator: Wei Liu, Genentech, a Member of the Roche Group 
    Scribe: Sharon (Xiao) Chen, MedImmune 

      To view the scope and discussion notes, click here.

 

   Table 58: Analytical Target Profiles
    Room: Palm Court Ballroom

    Facilitator: Juhong Liu, CDER, FDA
    Scribe: Ed Moore, University of Illinois

      To view the scope and discussion notes, click here.

 

   Table 59: Novel Modalities and their Comparability Challenges during Late Stage
    Development

    Room: Palm Court Ballroom

    Facilitator: Andy Weiskopf, Biogen 
    Scribe: Nick Bond, MedImmune

     To view the scope and discussion questions, click here.

 

   Table 60: Host Cell Protein: Implementing Risk Assessment Strategies
    Room: Palm Court Ballroom

    Facilitator: Markus Haindl, F. Hoffman - La Roche 
    Scribe: James Carroll, Pfizer, Inc.

      To view the scope and discussion notes, click here.

 

   Table 61: Regulation of Biologics in Africa: A Case Study in Ghana 
    Room: Palm Court Ballroom

    Facilitator: Eric Karikari-Boateng, Food and Drug Authority, Ghana
    Scribe: Fadi Hakki, MedImmune 

      To view the scope and discussion notes, click here.

 

    


 

 

 

Membership Software Powered by YourMembership  ::  Legal